Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02240680




Registration number
NCT02240680
Ethics application status
Date submitted
15/09/2014
Date registered
16/09/2014
Date last updated
3/07/2018

Titles & IDs
Public title
Linagliptin as Add on to Basal Insulin in the Elderly
Scientific title
A 24 Week Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Trial of Once Daily Linagliptin, 5 Milligrams Orally, as Add on to Basal Insulin in Elderly Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control
Secondary ID [1] 0 0
2014-000904-88
Secondary ID [2] 0 0
1218.149
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus, Type 2 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - placebo
Treatment: Drugs - linagliptin

Experimental: linagliptin 5 mg - patient to receive a tablet of linagliptin 5 mg each day

Placebo comparator: placebo - patient to receive a tablet of placebo matching linagliptin 5 mg


Treatment: Drugs: placebo
placebo matching linagliptin 5 mg

Treatment: Drugs: linagliptin
5 mg once a day
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Hemoglobin A1c (HbA1c) After 24 Weeks of Treatment.
Timepoint [1] 0 0
Baseline and Week 24
Secondary outcome [1] 0 0
Percentage of Patients Experiencing at Least One Hypoglycaemia Accompanied by a Prespecified Glucose Value.
Timepoint [1] 0 0
24 weeks
Secondary outcome [2] 0 0
Percentage of Patients With HbA1c<8.0%
Timepoint [2] 0 0
24 weeks
Secondary outcome [3] 0 0
Percentage of Patients With HbA1c on Treatment <7.0%
Timepoint [3] 0 0
24 weeks
Secondary outcome [4] 0 0
Percentage of Patients With HbA1c Lowering by at Least 0.5%.
Timepoint [4] 0 0
24 weeks
Secondary outcome [5] 0 0
Change From Baseline in Fasting Plasma Glucose (FPG)
Timepoint [5] 0 0
Baseline and Week 24

Eligibility
Key inclusion criteria
Inclusion criteria:

* Patients must sign and date an Informed Consent consistent with International Conference on Harmonisation and Good Clinical Practice guidelines and local regulations prior to any evaluation and participation in the trial.
* Male and female patients with a clinical diagnosis of Type 2 Diabetes Mellitus, at the time of Informed Consent, who are:
* 60 years of age or older at informed consent or Screen Visit,
* taking stable doses of basal or biosimilar basal insulin [strictly inclusive of: insulin neutral protamine Hagedorn and isophane insulin; Humalog Basal (a suspension of insulin lispro protamine); insulin degludec; insulin detemir; and insulin glargine] for at least 4 weeks prior to randomisation (Visit 3) with dose adjustments up to a maximum of plus or minus 20% of baseline being allowed,
* may or may not be taking metformin immediate release or extended release [if the patient is taking metformin, stable dose must be maintained for at least twelve weeks without dose adjustments prior to randomisation (Visit 3)], and
* may or may not be taking alpha-glucosidase inhibitors [acarbose, miglitol, and voglibose; if the patient is taking alpha-glucosidase inhibitors, stable dose must be maintained for at least twelve weeks without dose adjustments prior to randomisation (Visit 3)].
* Patients must have an glycosylated Haemoglobin of 7.0% (53 millimoles per mole) to 10.0% (86 millimoles per mole) at the first visit (Screen).
* Patients must have a Body Mass Index of 45 kilogram/meter squared or less at the Screen Visit.
* In the investigator's opinion, patients must be reliable, compliant, and agree to cooperate with all planned future trial evaluations as explained in detail during the informed consent process and to be able to perform them.
Minimum age
60 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

* Impaired cognitive ability as supported by the Saint Louis University Mental Status Examination, additional assessment if necessary, and verified by the investigator at the Screen Visit.
* Depressed mood as supported by a score of 10 or more on the Patient Health Questionnaire at the Screen Visit.
* Type 1 Diabetes Mellitus as determined by past medical records and history.
* Acute coronary syndrome (non-ST Elevation Myocardial Infarction, ST Elevation Myocardial Infarction, and/or unstable angina pectoris), stroke or transient ischemic attack within 3 months prior to Screen Visit.
* Indication of liver disease determined during Screen and/or Run-In Period, defined by a serum level above 3 times the upper limit of normal in any of the following: alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase.
* Bariatric, gastric bypass, and other gastrointestinal procedures or surgeries (including all types of gastric banding, restriction, and/or LapBand) with the objective of promoting weight loss within the past two years at Screen Visit.
* Medical history of cancer (except for resected non-invasive basal or squamous cell carcinoma) and/or treatment for cancer within the last 5 years.
* Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells (malaria, babesiosis, haemolytic anaemia).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
23/09/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
25/04/2017
Sample size
Target
Accrual to date
Final
302
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
AIM Centre - Merewether
Recruitment hospital [2] 0 0
Royal Brisbane & Women's Hospital-Endocrinology - Herston
Recruitment hospital [3] 0 0
ECRU Maroondah - East Ringwood
Recruitment postcode(s) [1] 0 0
2291 - Merewether
Recruitment postcode(s) [2] 0 0
4029 - Herston
Recruitment postcode(s) [3] 0 0
3135 - East Ringwood
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Nevada
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Pennsylvania
Country [12] 0 0
United States of America
State/province [12] 0 0
South Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Tennessee
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Utah
Country [16] 0 0
United States of America
State/province [16] 0 0
Virginia
Country [17] 0 0
United States of America
State/province [17] 0 0
Washington
Country [18] 0 0
United States of America
State/province [18] 0 0
Wisconsin
Country [19] 0 0
Belgium
State/province [19] 0 0
Oostham
Country [20] 0 0
Colombia
State/province [20] 0 0
Armenia
Country [21] 0 0
Colombia
State/province [21] 0 0
Bogotá
Country [22] 0 0
Colombia
State/province [22] 0 0
Manizales
Country [23] 0 0
Colombia
State/province [23] 0 0
Medellín
Country [24] 0 0
Denmark
State/province [24] 0 0
Aalborg
Country [25] 0 0
Denmark
State/province [25] 0 0
Esbjerg
Country [26] 0 0
Denmark
State/province [26] 0 0
Frederiksberg
Country [27] 0 0
Denmark
State/province [27] 0 0
Hellerup
Country [28] 0 0
Denmark
State/province [28] 0 0
Kolding
Country [29] 0 0
Denmark
State/province [29] 0 0
København NV
Country [30] 0 0
Denmark
State/province [30] 0 0
Køge
Country [31] 0 0
Denmark
State/province [31] 0 0
Roskilde
Country [32] 0 0
Finland
State/province [32] 0 0
Kerava
Country [33] 0 0
Finland
State/province [33] 0 0
Oulu
Country [34] 0 0
Finland
State/province [34] 0 0
Turku
Country [35] 0 0
Germany
State/province [35] 0 0
Asslar
Country [36] 0 0
Germany
State/province [36] 0 0
Berlin
Country [37] 0 0
Germany
State/province [37] 0 0
Bosenheim
Country [38] 0 0
Germany
State/province [38] 0 0
Koeln
Country [39] 0 0
Germany
State/province [39] 0 0
Rodgau
Country [40] 0 0
Germany
State/province [40] 0 0
Unterschneidheim
Country [41] 0 0
Greece
State/province [41] 0 0
Athens
Country [42] 0 0
Greece
State/province [42] 0 0
Ioannina
Country [43] 0 0
Greece
State/province [43] 0 0
Kifisia
Country [44] 0 0
Greece
State/province [44] 0 0
Nikaia
Country [45] 0 0
Greece
State/province [45] 0 0
Thessaloniki
Country [46] 0 0
Ireland
State/province [46] 0 0
Dublin
Country [47] 0 0
Japan
State/province [47] 0 0
Aichi, Nagoya
Country [48] 0 0
Japan
State/province [48] 0 0
Ehime, Matsuyama
Country [49] 0 0
Japan
State/province [49] 0 0
Gunma, Maebashi
Country [50] 0 0
Japan
State/province [50] 0 0
Hokkaido, Bibai
Country [51] 0 0
Japan
State/province [51] 0 0
Hokkaido, Hakodate
Country [52] 0 0
Japan
State/province [52] 0 0
Hokkaido, Obihiro
Country [53] 0 0
Japan
State/province [53] 0 0
Hokkaido, Sapporo
Country [54] 0 0
Japan
State/province [54] 0 0
Ibaraki, Koga
Country [55] 0 0
Japan
State/province [55] 0 0
Ibaraki, Naka
Country [56] 0 0
Japan
State/province [56] 0 0
Kanagawa, Kamakura
Country [57] 0 0
Japan
State/province [57] 0 0
Kanagawa, Sagamihara
Country [58] 0 0
Japan
State/province [58] 0 0
Kanagawa, Yokohama
Country [59] 0 0
Japan
State/province [59] 0 0
Okayama, Okayama
Country [60] 0 0
Japan
State/province [60] 0 0
Osaka, Osaka
Country [61] 0 0
Japan
State/province [61] 0 0
Osaka, Suita
Country [62] 0 0
Japan
State/province [62] 0 0
Saga, Saga
Country [63] 0 0
Japan
State/province [63] 0 0
Saitama, Kawagoe
Country [64] 0 0
Japan
State/province [64] 0 0
Shizuoka, Hamamatsu
Country [65] 0 0
Japan
State/province [65] 0 0
Tokyo, Adachi-ku
Country [66] 0 0
Japan
State/province [66] 0 0
Tokyo, Chuo-ku
Country [67] 0 0
Japan
State/province [67] 0 0
Tokyo, Koto-ku
Country [68] 0 0
Japan
State/province [68] 0 0
Tokyo, Kunitachi
Country [69] 0 0
Japan
State/province [69] 0 0
Tokyo, Shibuya-ku
Country [70] 0 0
Mexico
State/province [70] 0 0
Chihuahua
Country [71] 0 0
Mexico
State/province [71] 0 0
Mexico
Country [72] 0 0
Mexico
State/province [72] 0 0
México
Country [73] 0 0
Mexico
State/province [73] 0 0
Pachuca
Country [74] 0 0
New Zealand
State/province [74] 0 0
Auckland, New Zealand
Country [75] 0 0
New Zealand
State/province [75] 0 0
Auckland
Country [76] 0 0
New Zealand
State/province [76] 0 0
Christchurch
Country [77] 0 0
Poland
State/province [77] 0 0
Oswiecim
Country [78] 0 0
Poland
State/province [78] 0 0
Poznan
Country [79] 0 0
Poland
State/province [79] 0 0
Warszawa
Country [80] 0 0
Romania
State/province [80] 0 0
Bucharest
Country [81] 0 0
Romania
State/province [81] 0 0
Oradea
Country [82] 0 0
Romania
State/province [82] 0 0
Tirgu Mures
Country [83] 0 0
South Africa
State/province [83] 0 0
Cape Town
Country [84] 0 0
South Africa
State/province [84] 0 0
Johannesburg
Country [85] 0 0
South Africa
State/province [85] 0 0
KwaMhlanga
Country [86] 0 0
South Africa
State/province [86] 0 0
Middleburg
Country [87] 0 0
South Africa
State/province [87] 0 0
Pretoria
Country [88] 0 0
Spain
State/province [88] 0 0
A Coruña
Country [89] 0 0
Spain
State/province [89] 0 0
Alicante
Country [90] 0 0
Spain
State/province [90] 0 0
Barcelona
Country [91] 0 0
Spain
State/province [91] 0 0
Canet de Mar
Country [92] 0 0
Spain
State/province [92] 0 0
Malaga
Country [93] 0 0
Spain
State/province [93] 0 0
Sevilla
Country [94] 0 0
Spain
State/province [94] 0 0
Valencia
Country [95] 0 0
Spain
State/province [95] 0 0
Vic
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Burnhope
Country [97] 0 0
United Kingdom
State/province [97] 0 0
Doncaster
Country [98] 0 0
United Kingdom
State/province [98] 0 0
Fowey
Country [99] 0 0
United Kingdom
State/province [99] 0 0
Liskeard
Country [100] 0 0
United Kingdom
State/province [100] 0 0
Newport
Country [101] 0 0
United Kingdom
State/province [101] 0 0
Penzance
Country [102] 0 0
United Kingdom
State/province [102] 0 0
Torpoint

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Boehringer Ingelheim
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Eli Lilly and Company
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
To investigate the efficacy, safety, and tolerability of linagliptin 5 milligrams once a day compared to placebo as as add-on therapy for 24 weeks to stable basal insulin treatment in elderly patients, 60 years of age and older, with Type 2 Diabetes Mellitus and insufficient glycaemic control.Stable background therapy of metformin and/or alpha-glucosidase inhibitors is also allowed.

In addition, this trial will assess if linagliptin reduces the risk of hypoglycaemia when added to background basal insulin therapy. The treatment duration of this trial (24 weeks) will enable assessment of the clinically relevant endpoint of a decrease in glycosylated Haemoglobin, a well-accepted measurement of chronic glycaemic control.
Trial website
https://clinicaltrials.gov/study/NCT02240680
Trial related presentations / publications
Araki E, Unno Y, Tanaka Y, Sakamoto W, Miyamoto Y. Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged >/= 60 Years Treated with Basal Insulin: A Randomised Trial. Adv Ther. 2019 Oct;36(10):2697-2711. doi: 10.1007/s12325-019-01065-7. Epub 2019 Sep 3.
Public notes

Contacts
Principal investigator
Name 0 0
Boehringer Ingelheim
Address 0 0
Boehringer Ingelheim
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02240680